CAMBRIDGE, Mass., Dec. 18,
2024 /PRNewswire/ -- Blueprint Medicines Corporation
(Nasdaq: BPMC) today announced that Kate
Haviland, Chief Executive Officer, will present a corporate
overview and 2025 outlook at the 43rd Annual J.P. Morgan
Healthcare Conference on Monday, January 13,
2025, at 9:00 a.m. PT
(12:00 p.m. ET).
A live webcast of the presentation will be available by visiting
the Investors & Media section of Blueprint Medicines' website
at http://ir.blueprintmedicines.com. A replay of the webcast will
be archived on Blueprint Medicines' website for 30 days following
the presentation.
About Blueprint Medicines
Blueprint Medicines is a global, fully integrated
biopharmaceutical company that invents life-changing medicines. We
seek to alleviate human suffering by solving important medical
problems in two core focus areas: allergy/inflammation and
oncology/hematology. Our approach begins by targeting the root
causes of disease, using deep scientific knowledge in our core
focus areas and drug discovery expertise across multiple
therapeutic modalities. We have a track record of success with two
approved medicines, including
AYVAKIT®/AYVAKYT® (avapritinib) which we are
bringing to patients with systemic mastocytosis (SM) in the U.S.
and Europe. Leveraging our
established research, development, and commercial capability and
infrastructure, we now aim to significantly scale our impact by
advancing a broad pipeline of programs ranging from early science
to advanced clinical trials in mast cell diseases including SM and
chronic urticaria, breast cancer and other solid tumors. For more
information, visit www.BlueprintMedicines.com and follow us on X
(formerly Twitter; @BlueprintMeds) and LinkedIn.
Trademarks
Blueprint Medicines, AYVAKIT, AYVAKYT and associated logos are
trademarks of Blueprint Medicines Corporation.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/blueprint-medicines-to-present-at-the-43rd-annual-jp-morgan-healthcare-conference-302334060.html
SOURCE Blueprint Medicines Corporation
